This test is most useful if any of these apply to you.
MHPG stands for 3-methoxy-4-hydroxyphenylglycol. Your body produces it while breaking down norepinephrine. Norepinephrine is a chemical messenger involved in alertness, attention, and the control of blood vessels and other organs. The amount of MHPG reaching your urine depends on several steps in that breakdown process, so it doesn't translate directly into how stressed you feel or how much norepinephrine your brain releases.
Urinary MHPG remains an exploratory marker for stress, mood, and preventive health. It has been studied for decades, but research hasn't established a target that predicts better health or shown that routine monitoring improves outcomes. A personal baseline records your excretion under particular conditions; its value for guiding health decisions is unproven.
Norepinephrine is broken down both within nerve cells and in other tissues. MHPG is one product of this process. The liver converts much of it into vanillylmandelic acid, or VMA, which the kidneys then remove. In a tracer study involving five healthy men, about 40% of injected, labeled MHPG was recovered in urine as VMA. Another 40% appeared as chemically attached forms of MHPG. Those figures describe the injected dose in that experiment, rather than a fixed distribution in everyone.
Most urinary MHPG is attached to other chemical groups. These attached forms are called conjugates. In one study of 28 healthy adults, about 52% was attached to glucuronide, 40% to sulfate, and 8% was free. Total urinary MHPG combines these forms.
Early experiments suggested that the glucuronide form mainly reflected nerves outside the brain, while the sulfate form might carry more information about the brain. Later human research measured blood entering and leaving abdominal organs and identified the gut and related organs as the main source of sulfate-conjugated MHPG. Separating the two urinary forms therefore doesn't reliably separate brain activity from activity elsewhere in your body.
Researchers initially hoped urinary MHPG would provide a practical window into brain norepinephrine metabolism. The relationship is less direct than that. In a study that collected urine, blood, and spinal fluid simultaneously from 16 people, total MHPG in blood and spinal fluid tracked together closely, while urinary MHPG wasn't significantly correlated with either. That finding limits the interpretation of urine results; it doesn't establish that the measurements can never correlate in another population.
Urinary MHPG reflects a mixture of production, chemical processing, and elimination. A change can occur because norepinephrine metabolism changed, because more MHPG was converted to VMA, or because the balance of its free and attached forms changed. Calling the result a measure of your brain's chemical balance or a score for chronic stress goes beyond what has been established.
The findings in mood disorders have been inconsistent. One study found lower urinary MHPG in 14 women with depression than in 10 healthy comparison women. In the same study, higher MHPG was associated with agitation in women with schizophrenia, but that association wasn't found in the depressed group.
Daily observations in two people with bipolar disorder found higher excretion during mania and lower excretion during depression. Such a small study can suggest a relationship, but it can't establish a dependable way to recognize or predict mood episodes. A later analysis of data collected at the US National Institute of Mental Health found that MHPG didn't significantly distinguish unipolar depression, bipolar depression, and healthy volunteers.
Studies have also investigated whether urinary MHPG could help select antidepressants. Results have conflicted. In one study of 64 people with depression, average pretreatment MHPG from repeated 24-hour collections didn't predict treatment response. These findings don't support using your result to diagnose depression, distinguish depression from bipolar disorder, or choose a medication.
An older study compared morning urine from 41 people with Parkinson's disease who weren't taking medication with samples from 25 hospitalized controls. MHPG excretion was higher in the Parkinson's group, but the statistically supported difference was confined to the subgroup whose main symptom was difficulty initiating movement. The study didn't establish urinary MHPG as a diagnostic or monitoring test for Parkinson's disease.
More recent research found lower urinary norepinephrine and dopamine in Parkinson's disease, multiple system atrophy, and pure autonomic failure. Those are different molecules from MHPG. Their results can't be used to decide whether a urinary MHPG result indicates nerve loss or to reconcile the older findings into a single disease pattern.
In a study of 30 people with an acute heart attack, urinary MHPG was higher than in controls. It didn't distinguish uncomplicated recoveries from those with complications. This shows that serious illness can change the measurement, but it doesn't establish a role for predicting a future heart attack or assessing recovery.
Some pheochromocytomas and paragangliomas produce excess norepinephrine or adrenaline. An older study found higher free and conjugated urinary MHPG in people with pheochromocytoma. Established testing for these tumors uses plasma free metanephrines or 24-hour urinary fractionated metanephrines. Urinary MHPG hasn't been validated as a substitute.
Repeated measurements under similar conditions can help establish whether a difference persists. They don't resolve the uncertainty about what that difference means. There is no validated amount of change that establishes improved stress resilience, better mood, or slower aging, and a lower result isn't automatically healthier.
3-Methyl-4-Hydroxyphenylglycol is best interpreted alongside these tests.
3-Methyl-4-Hydroxyphenylglycol is included in these pre-built panels.
See the chemical trail your metabolism leaves behind, and explore where your energy, gut, and nutrient pathways may be under strain.
A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.
90 biomarkers